A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506805-20-01

Enrollment

Registered

2024-08-20

Start date

2024-09-25

Completion date

2026-01-05

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative Diseases

Brief summary

Number of participants receiving latozinemab, Duration of treatment

Detailed description

Number, percentages, nature, and severity of adverse events (AEs) and serious adverse events (SAEs), Number and percentage of cases of the development of ADAs to latozinemab, Actual values of the CGI-S every 3 months, Actual values of the CGI-I every 3 months

Interventions

DRUGlatozinemab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants receiving latozinemab, Duration of treatment	—

Secondary

Measure	Time frame
Number, percentages, nature, and severity of adverse events (AEs) and serious adverse events (SAEs), Number and percentage of cases of the development of ADAs to latozinemab, Actual values of the CGI-S every 3 months, Actual values of the CGI-I every 3 months	—

Countries

Belgium, France, Germany, Italy, Netherlands, Portugal, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026